U.S. FDA declines to approve Spectrum Pharmaceuticals' lung cancer drug
25/11/2022 11:06
Nov 25 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O
said on Friday the U.S. Food and Drug Administration (FDA)
declined to approve its experimental drug for the treatment of
patients with a form of non-small cell lung cancer.
The health regulator's decision is in line with an advisory
panel's recommendation to not approve the drug due to
questionable efficacy and lack of dose optimization.
(Reporting by Khushi Mandowara; Editing by Krishna Chandra
Eluri and Devika Syamnath)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary